FDA Adds Another Player in ALK-Positive Lung Cancer
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.